Open AccessOutcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case–Control Matched Analysis
Author(s) -
Abhishek Chopra,
Jacob C. Hodges,
Adam C. Olson,
S.A. Burton,
Susannah G. Ellsworth,
Nathan Bahary,
Aatur D. Singhi,
Brian A. Boone,
Joal D. Beane,
David L. Bartlett,
Kenneth K. Lee,
Melissa E. Hogg,
Michael T. Lotze,
Alessandro Paniccia,
Herbert J. Zeh,
Amer H. Zureikat
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-09391-9
Subject(s) - medicine , oncology , gemcitabine , surgical oncology , neoadjuvant therapy , chemotherapy , regimen , pancreatic cancer , lymphovascular invasion , adenocarcinoma , gastroenterology , cancer , surgery , metastasis , breast cancer
Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and survival outcomes of NCRT and NAC in patients with PDAC.